﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2011v1.2">
  <ReturnHeader binaryAttachmentCount="0">
    <Timestamp>2012-11-14T08:24:07-06:00</Timestamp>
    <TaxPeriodEndDate>2011-12-31</TaxPeriodEndDate>
    <PreparerFirm>
      <EIN>560747981</EIN>
      <PreparerFirmBusinessName>
        <BusinessNameLine1>DIXON HUGHES GOODMAN LLP</BusinessNameLine1>
      </PreparerFirmBusinessName>
      <PreparerFirmUSAddress>
        <AddressLine1>111 ROCKVILLE PIKE 6TH FLOOR</AddressLine1>
        <City>ROCKVILLE</City>
        <State>MD</State>
        <ZIPCode>20850</ZIPCode>
      </PreparerFirmUSAddress>
    </PreparerFirm>
    <ReturnType>990</ReturnType>
    <TaxPeriodBeginDate>2011-01-01</TaxPeriodBeginDate>
    <Filer>
      <EIN>521986675</EIN>
      <Name>
        <BusinessNameLine1>FOUNDATION FOR THE NATIONAL INSTITUTES</BusinessNameLine1>
        <BusinessNameLine2>OF HEALTH INC</BusinessNameLine2>
      </Name>
      <NameControl>FOUN</NameControl>
      <Phone>3014025311</Phone>
      <USAddress>
        <AddressLine1>9650 ROCKVILLE PIKE NO 3411</AddressLine1>
        <City>BETHESDA</City>
        <State>MD</State>
        <ZIPCode>20814</ZIPCode>
      </USAddress>
    </Filer>
    <Officer>
      <Name>STEPHANIE JAMES PHD</Name>
      <Title>INTERIM DIRECTOR</Title>
      <Phone>3014025311</Phone>
      <DateSigned>2012-11-08</DateSigned>
      <AuthorizeThirdParty>1</AuthorizeThirdParty>
    </Officer>
    <Preparer>
      <Name>ROBIN SKINNER CPA</Name>
      <PTIN>P00742964</PTIN>
      <Phone>2404033700</Phone>
    </Preparer>
    <TaxYear>2011</TaxYear>
    <BuildTS>2016-02-24 21:20:13Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCount="8">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <NameOfPrincipalOfficerPerson>STEPHANIE JAMES PHD</NameOfPrincipalOfficerPerson>
      <AddressPrincipalOfficerUS>
        <AddressLine1>9650 ROCKVILLE PIKE NO 3411</AddressLine1>
        <City>BETHESDA</City>
        <State>MD</State>
        <ZIPCode>20814</ZIPCode>
      </AddressPrincipalOfficerUS>
      <GrossReceipts>107510023</GrossReceipts>
      <GroupReturnForAffiliates>0</GroupReturnForAffiliates>
      <Organization501c3>X</Organization501c3>
      <WebSite>HTTP://WWW.FNIH.ORG</WebSite>
      <TypeOfOrganizationCorporation>X</TypeOfOrganizationCorporation>
      <YearFormation>2001</YearFormation>
      <StateLegalDomicile>MD</StateLegalDomicile>
      <ActivityOrMissionDescription>THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) WAS ESTABLISHED BY CONGRESS TO SUPPORT THE MISSION OF THE NATIONAL INSTITUTES OF HEALTH (NIH): IMPROVING HEALTH THROUGH SCIENTIFIC DISCOVERY. IN 2011, FNIH ORGANIZED EVENTS SPANNING DOZENS OF FIELDS AND MADE IMPORTANT PROGRESS IN ADVANCING HUMAN HEALTH.</ActivityOrMissionDescription>
      <NbrVotingMembersGoverningBody>26</NbrVotingMembersGoverningBody>
      <NbrIndependentVotingMembers>26</NbrIndependentVotingMembers>
      <TotalNbrEmployees>45</TotalNbrEmployees>
      <TotalNbrVolunteers>0</TotalNbrVolunteers>
      <TotalGrossUBI>0</TotalGrossUBI>
      <NetUnrelatedBusinessTxblIncome>0</NetUnrelatedBusinessTxblIncome>
      <ContributionsGrantsPriorYear>62671114</ContributionsGrantsPriorYear>
      <ContributionsGrantsCurrentYear>59765254</ContributionsGrantsCurrentYear>
      <ProgramServiceRevenuePriorYear>300796</ProgramServiceRevenuePriorYear>
      <ProgramServiceRevenueCY>1549687</ProgramServiceRevenueCY>
      <InvestmentIncomePriorYear>164193</InvestmentIncomePriorYear>
      <InvestmentIncomeCurrentYear>135308</InvestmentIncomeCurrentYear>
      <OtherRevenuePriorYear>0</OtherRevenuePriorYear>
      <OtherRevenueCurrentYear>0</OtherRevenueCurrentYear>
      <TotalRevenuePriorYear>63136103</TotalRevenuePriorYear>
      <TotalRevenueCurrentYear>61450249</TotalRevenueCurrentYear>
      <GrantsAndSimilarAmntsPriorYear>26565461</GrantsAndSimilarAmntsPriorYear>
      <GrantsAndSimilarAmntsCY>25483921</GrantsAndSimilarAmntsCY>
      <BenefitsPaidToMembersPriorYear>0</BenefitsPaidToMembersPriorYear>
      <BenefitsPaidToMembersCY>0</BenefitsPaidToMembersCY>
      <SalariesEtcPriorYear>5267527</SalariesEtcPriorYear>
      <SalariesEtcCurrentYear>5571047</SalariesEtcCurrentYear>
      <TotalProfFundrsngExpPriorYear>0</TotalProfFundrsngExpPriorYear>
      <TotalProfFundrsngExpCY>0</TotalProfFundrsngExpCY>
      <TotalFundrsngExpCurrentYear>141344</TotalFundrsngExpCurrentYear>
      <OtherExpensePriorYear>21785156</OtherExpensePriorYear>
      <OtherExpensesCurrentYear>19448911</OtherExpensesCurrentYear>
      <TotalExpensesPriorYear>53618144</TotalExpensesPriorYear>
      <TotalExpensesCurrentYear>50503879</TotalExpensesCurrentYear>
      <RevenuesLessExpensesPriorYear>9517959</RevenuesLessExpensesPriorYear>
      <RevenuesLessExpensesCY>10946370</RevenuesLessExpensesCY>
      <TotalAssetsBOY>91290841</TotalAssetsBOY>
      <TotalAssetsEOY>98055767</TotalAssetsEOY>
      <TotalLiabilitiesBOY>17752722</TotalLiabilitiesBOY>
      <TotalLiabilitiesEOY>13622823</TotalLiabilitiesEOY>
      <NetAssetsOrFundBalancesBOY>73538119</NetAssetsOrFundBalancesBOY>
      <NetAssetsOrFundBalancesEOY>84432944</NetAssetsOrFundBalancesEOY>
      <InfoInScheduleOPartIII>X</InfoInScheduleOPartIII>
      <MissionDescription>SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENT</MissionDescription>
      <SignificantNewProgramServices>0</SignificantNewProgramServices>
      <SignificantChange>0</SignificantChange>
      <Expense>42338276</Expense>
      <Grants>25204871</Grants>
      <Revenue>1549687</Revenue>
      <Description>SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPS</Description>
      <Activity2>
        <Expense>1486681</Expense>
        <Grants>243600</Grants>
        <Description>SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMS</Description>
      </Activity2>
      <Activity3>
        <Expense>38516</Expense>
        <Description>SEE SCHEDULE O, PROGRAM THREE, CAPITAL PROJECTS</Description>
      </Activity3>
      <ActivityOther>
        <Expense>3712399</Expense>
        <Grants>35450</Grants>
        <Description>SEE SCHEDULE O, MEMORIALS, AWARDS AND EVENTS</Description>
      </ActivityOther>
      <TotalOfOtherProgramServiceExp>3712399</TotalOfOtherProgramServiceExp>
      <TotalOfOtherProgramServiceGrnt>35450</TotalOfOtherProgramServiceGrnt>
      <TotalProgramServiceExpense>47575872</TotalProgramServiceExpense>
      <DescribedIn501C3 referenceDocumentId="RetDoc1039100001">1</DescribedIn501C3>
      <ScheduleBRequired referenceDocumentId="RetDoc1234500001">1</ScheduleBRequired>
      <PoliticalActivities>0</PoliticalActivities>
      <LobbyingActivities>0</LobbyingActivities>
      <SubjectToProxyTax>0</SubjectToProxyTax>
      <DonorAdvisedFunds referenceDocumentId="RetDoc1039900001">1</DonorAdvisedFunds>
      <ConservationEasements referenceDocumentId="RetDoc1039900001">0</ConservationEasements>
      <CollectionsOfArt referenceDocumentId="RetDoc1039900001">0</CollectionsOfArt>
      <CreditCounseling referenceDocumentId="RetDoc1039900001">1</CreditCounseling>
      <TermOrPermanentEndowments referenceDocumentId="RetDoc1039900001">1</TermOrPermanentEndowments>
      <ReportLandBldgEquip referenceDocumentId="RetDoc1039900001">1</ReportLandBldgEquip>
      <ReportInvestOthSecurities referenceDocumentId="RetDoc1039900001">1</ReportInvestOthSecurities>
      <ReportProgRelInvest referenceDocumentId="RetDoc1039900001">0</ReportProgRelInvest>
      <ReportOtherAssets referenceDocumentId="RetDoc1039900001">0</ReportOtherAssets>
      <ReportOtherLiabilities referenceDocumentId="RetDoc1039900001">0</ReportOtherLiabilities>
      <ReportFin48Footnote referenceDocumentId="RetDoc1039900001">1</ReportFin48Footnote>
      <IndependentAuditFinancialStmt referenceDocumentId="RetDoc1039900001">1</IndependentAuditFinancialStmt>
      <ConsolidatedAuditFinancialStmt referenceDocumentId="RetDoc1039900001">0</ConsolidatedAuditFinancialStmt>
      <School>0</School>
      <ForeignOffice>0</ForeignOffice>
      <ForeignActivities referenceDocumentId="RetDoc1040500001">0</ForeignActivities>
      <MoreThan5000KToOrganizations referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrganizations>
      <MoreThan5000KToIndividuals referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividuals>
      <ProfessionalFundraising>0</ProfessionalFundraising>
      <FundraisingActivities>0</FundraisingActivities>
      <Gaming>0</Gaming>
      <Hospital>0</Hospital>
      <GrantsToOrganizations referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizations>
      <GrantsToIndividuals referenceDocumentId="RetDoc1041900001">1</GrantsToIndividuals>
      <ScheduleJRequired referenceDocumentId="RetDoc1042400001">1</ScheduleJRequired>
      <TaxExemptBonds>0</TaxExemptBonds>
      <ExcessBenefitTransaction>0</ExcessBenefitTransaction>
      <PriorExcessBenefitTransaction>0</PriorExcessBenefitTransaction>
      <LoanToOfficerOrDQP>0</LoanToOfficerOrDQP>
      <GrantToRelatedPerson>0</GrantToRelatedPerson>
      <BsnssRltnshpWithOrganization>0</BsnssRltnshpWithOrganization>
      <BsnssRltnshpThruFamilyMember>0</BsnssRltnshpThruFamilyMember>
      <OfficerEntityWithBsnssRltnshp>0</OfficerEntityWithBsnssRltnshp>
      <DeductibleNonCashContributions>0</DeductibleNonCashContributions>
      <DeductibleContributionsOfArt>0</DeductibleContributionsOfArt>
      <Terminated>0</Terminated>
      <PartialLiquidation>0</PartialLiquidation>
      <DisregardedEntity>0</DisregardedEntity>
      <RelatedEntity>0</RelatedEntity>
      <RelatedOrgControlledEntity>0</RelatedOrgControlledEntity>
      <TransactionRelatedEntity>0</TransactionRelatedEntity>
      <TransfersToExemptNonChrtblOrg>0</TransfersToExemptNonChrtblOrg>
      <ActivitiesConductedPartnership>0</ActivitiesConductedPartnership>
      <ScheduleORequired>1</ScheduleORequired>
      <NumberFormsTransmittedWith1096>41</NumberFormsTransmittedWith1096>
      <NumberW2GIncluded>0</NumberW2GIncluded>
      <ComplianceWithBackupWitholding>1</ComplianceWithBackupWitholding>
      <NumberOfEmployees>45</NumberOfEmployees>
      <EmploymentTaxReturnsFiled>1</EmploymentTaxReturnsFiled>
      <UnrelatedBusinessIncome>0</UnrelatedBusinessIncome>
      <ForeignFinancialAccount>0</ForeignFinancialAccount>
      <ProhibitedTaxShelterTrans>0</ProhibitedTaxShelterTrans>
      <TaxablePartyNotification>0</TaxablePartyNotification>
      <NonDeductibleContributions>0</NonDeductibleContributions>
      <QuidProQuoContributions>0</QuidProQuoContributions>
      <Form8282PropertyDisposedOf>0</Form8282PropertyDisposedOf>
      <FundsToPayPremiums>0</FundsToPayPremiums>
      <PremiumsPaid>0</PremiumsPaid>
      <ExcessBusinessHoldings>0</ExcessBusinessHoldings>
      <TaxableDistributions>0</TaxableDistributions>
      <DistributionToDonor>0</DistributionToDonor>
      <IndoorTanningServices>0</IndoorTanningServices>
      <InfoInScheduleOPartVI>X</InfoInScheduleOPartVI>
      <NbrVotingGoverningBodyMembers>26</NbrVotingGoverningBodyMembers>
      <NumberIndependentVotingMembers>26</NumberIndependentVotingMembers>
      <FamilyOrBusinessRelationship>0</FamilyOrBusinessRelationship>
      <DelegationOfManagementDuties>0</DelegationOfManagementDuties>
      <ChangesToOrganizingDocs>1</ChangesToOrganizingDocs>
      <MaterialDiversionOrMisuse>0</MaterialDiversionOrMisuse>
      <MembersOrStockholders>0</MembersOrStockholders>
      <ElectionOfBoardMembers>0</ElectionOfBoardMembers>
      <DecisionsSubjectToApproval>0</DecisionsSubjectToApproval>
      <MinutesOfGoverningBody>1</MinutesOfGoverningBody>
      <MinutesOfCommittees>1</MinutesOfCommittees>
      <OfficerMailingAddress>0</OfficerMailingAddress>
      <LocalChapters>0</LocalChapters>
      <Form990ProvidedToGoverningBody>1</Form990ProvidedToGoverningBody>
      <ConflictOfInterestPolicy>1</ConflictOfInterestPolicy>
      <AnnualDisclosureCoveredPersons>1</AnnualDisclosureCoveredPersons>
      <RegularMonitoringEnforcement>1</RegularMonitoringEnforcement>
      <WhistleblowerPolicy>1</WhistleblowerPolicy>
      <DocumentRetentionPolicy>1</DocumentRetentionPolicy>
      <CompensationProcessCEO>1</CompensationProcessCEO>
      <CompensationProcessOther>1</CompensationProcessOther>
      <InvestmentInJointVenture>0</InvestmentInJointVenture>
      <StatesWhereCopyOfReturnIsFiled>MD</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>VA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NY</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AK</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AZ</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AR</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>CA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>CO</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>CT</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>FL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>GA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>HI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>IL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>KS</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>KY</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>ME</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MS</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MN</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NH</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NJ</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NM</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NC</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>ND</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>OH</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>OK</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>OR</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>PA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>RI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>SC</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>TN</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>UT</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>WA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>WV</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>WI</StatesWhereCopyOfReturnIsFiled>
      <OwnWebsite>X</OwnWebsite>
      <UponRequest>X</UponRequest>
      <TheBooksAreInCareOf>
        <NameBusiness>
          <BusinessNameLine1>JULIE TUNE</BusinessNameLine1>
        </NameBusiness>
        <TelephoneNumber>3014025311</TelephoneNumber>
        <AddressUS>
          <AddressLine1>9650 ROCKVILLE PIKE</AddressLine1>
          <City>BETHESDA</City>
          <State>MD</State>
          <ZIPCode>20814</ZIPCode>
        </AddressUS>
      </TheBooksAreInCareOf>
      <Form990PartVIISectionA>
        <NamePerson>CHARLES A SANDERS MD</NamePerson>
        <Title>CHAIRMAN</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>PAUL M MONTRONE PHD</NamePerson>
        <Title>TREASURER</Title>
        <AverageHoursPerWeek>1.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JOHN EDWARD PORTER</NamePerson>
        <Title>VICE CHAIRMAN</Title>
        <AverageHoursPerWeek>1.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MRS WILLIAM MCCORMICK BLAIR</NamePerson>
        <Title>SECRETARY</Title>
        <AverageHoursPerWeek>1.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KATHY BLOOMGARDEN PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MRS WILLIAM N CAFRITZ</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANN LURIE</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JOSEPH M FECZKO MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MILES GILBURNE</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>CAROLINE A KOVAC PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>SHERRY LANSING</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MARTIN MURPHY JR PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>STEVEN M PAUL MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>PHILIP A PIZZO MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JILLIAN SACKLER DBE</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>LILY SAFRA</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KURT L SCHMOKE JD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ELLEN V SIGAL PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>SOLOMON H SNYDER MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>STEPHEN SPIELBERGMDPHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>SAMUEL O THIER MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>PATRICK C WALSH MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANNE WOJCICKI</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>PAUL BERG PHD</NamePerson>
        <Title>DIRECTOR EMERITUS</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>LUTHER W BRADY MD</NamePerson>
        <Title>HONORARY DIRECTOR</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>FREDA LEWIS-HALL MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>0.50</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>SCOTT CAMPBELL</NamePerson>
        <Title>EXECUTIVE DIRECTOR AND CEO</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>222288</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>26825</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>DAVID WHOLLEY</NamePerson>
        <Title>DIR BIOMARKERS CONSORTIUM</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>258423</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>35802</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>STEPHANIE JAMES</NamePerson>
        <Title>DIR OF SCIENCE AND GCGH</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>261148</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>26115</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANDREA BARUCHIN</NamePerson>
        <Title>DIR NIH RELATIONS</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>182510</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>22847</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>RICHARD SCARFO</NamePerson>
        <Title>DIR MKTG AND STRATEGIC ALL</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>165114</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>26471</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JULIE TUNE</NamePerson>
        <Title>CHIEF FINANCIAL OFFICER</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>168143</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>26774</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANN ASHBY</NamePerson>
        <Title>DEPUTY EXECUTIVE DIRECTOR</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>193186</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>29279</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JULIE WOLF-RODDA</NamePerson>
        <Title>DIR PSHIP DEVELOPMENT</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>171808</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>27141</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MICHAEL GOTTLIEB</NamePerson>
        <Title>ASSOC DIR OF SCIENCE</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>214468</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>21447</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JUDITH SIUCIAK</NamePerson>
        <Title>SCIENTIFIC PROGRAM MANAGER</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>144870</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>24447</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>GAIL LEVINE</NamePerson>
        <Title>SCIENTIFIC PROGRAM MANAGER</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>136705</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>23631</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>SONIA PEARSON-WHITE</NamePerson>
        <Title>SCIENTIFIC PROGRAM MANAGER</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>117947</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>16391</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MARIA VASSILEVA</NamePerson>
        <Title>SCIENTIFIC PROGRAM MANAGER</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>112198</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>21180</OtherCompensation>
      </Form990PartVIISectionA>
      <TotalReportableCompFromOrg>2348808</TotalReportableCompFromOrg>
      <TotalReportableCompFrmRltdOrgs>0</TotalReportableCompFrmRltdOrgs>
      <TotalOtherCompensation>328350</TotalOtherCompensation>
      <NumberIndividualsGT100K>13</NumberIndividualsGT100K>
      <FormersListed>0</FormersListed>
      <TotalCompGT150K>1</TotalCompGT150K>
      <CompensationFromOtherSources>0</CompensationFromOtherSources>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>OGILVY PUBLIC RELATIONS WORLDWIDE</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>PO BOX 7242</AddressLine1>
            <City>PHILADELPHIA</City>
            <State>PA</State>
            <ZIPCode>19170</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>PROFESSIONAL SERVICES</DescriptionOfServices>
        <Compensation>936075</Compensation>
      </ContractorCompensation>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>EPHIR INC</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>PO BOX 253</AddressLine1>
            <City>SWAMPSCOTT</City>
            <State>MA</State>
            <ZIPCode>01907</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>RESARCH LAB RELEASE MANAGEMENT</DescriptionOfServices>
        <Compensation>676630</Compensation>
      </ContractorCompensation>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>DIGITAL AURORA</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>PO BOX 648 174 SARGENT LANE</AddressLine1>
            <City>MANCHESTER</City>
            <State>VT</State>
            <ZIPCode>05254</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>CONSULTING</DescriptionOfServices>
        <Compensation>590395</Compensation>
      </ContractorCompensation>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>SAS INSTITUTE INC</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>PO BOX 406922</AddressLine1>
            <City>ATLANTA</City>
            <State>GA</State>
            <ZIPCode>30384</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>INFORMATION TECHNOLOGY</DescriptionOfServices>
        <Compensation>500000</Compensation>
      </ContractorCompensation>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>GAYLORD NATIONAL LLC</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>WATERFRONT STREET</AddressLine1>
            <City>OXON HILL</City>
            <State>MD</State>
            <ZIPCode>20745</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>CONFERENCES AND MEETINGS</DescriptionOfServices>
        <Compensation>424978</Compensation>
      </ContractorCompensation>
      <NumberOfContractorsGT100K>5</NumberOfContractorsGT100K>
      <GovernmentGrants>486000</GovernmentGrants>
      <AllOtherContributions>59279254</AllOtherContributions>
      <TotalContributions>59765254</TotalContributions>
      <ProgramServiceRevenue>
        <Description>REGISTRATION AND EXHIB</Description>
        <BusinessCode>541700</BusinessCode>
        <TotalRevenueColumn>1212823</TotalRevenueColumn>
        <RelatedOrExemptFunctionIncome>1212823</RelatedOrExemptFunctionIncome>
      </ProgramServiceRevenue>
      <ProgramServiceRevenue>
        <Description>ADMINISTRATIVE FEES</Description>
        <BusinessCode>561000</BusinessCode>
        <TotalRevenueColumn>336864</TotalRevenueColumn>
        <RelatedOrExemptFunctionIncome>336864</RelatedOrExemptFunctionIncome>
      </ProgramServiceRevenue>
      <TotalProgramServiceRevenue>1549687</TotalProgramServiceRevenue>
      <InvestmentIncome>
        <TotalRevenueColumn>134140</TotalRevenueColumn>
        <ExclusionAmount>134140</ExclusionAmount>
      </InvestmentIncome>
      <GrossAmountSalesAssets>
        <Securities>46060942</Securities>
      </GrossAmountSalesAssets>
      <LessCostOthBasisSalesExpenses>
        <Securities>46059774</Securities>
      </LessCostOthBasisSalesExpenses>
      <GainOrLoss>
        <Securities>1168</Securities>
      </GainOrLoss>
      <NetGainOrLossInvestments>
        <TotalRevenueColumn>1168</TotalRevenueColumn>
        <ExclusionAmount>1168</ExclusionAmount>
      </NetGainOrLossInvestments>
      <TotalRevenue>
        <TotalRevenueColumn>61450249</TotalRevenueColumn>
        <RelatedOrExemptFunctionIncome>1549687</RelatedOrExemptFunctionIncome>
        <UnrelatedBusinessRevenue>0</UnrelatedBusinessRevenue>
        <ExclusionAmount>135308</ExclusionAmount>
      </TotalRevenue>
      <GrantsToDomesticOrgs>
        <Total>15513099</Total>
        <ProgramServices>15513099</ProgramServices>
      </GrantsToDomesticOrgs>
      <GrantsToDomesticIndividuals>
        <Total>288050</Total>
        <ProgramServices>288050</ProgramServices>
      </GrantsToDomesticIndividuals>
      <ForeignGrants>
        <Total>9682772</Total>
        <ProgramServices>9682772</ProgramServices>
      </ForeignGrants>
      <CompCurrentOfficersDirectors>
        <Total>2677158</Total>
        <ProgramServices>1705328</ProgramServices>
        <ManagementAndGeneral>959558</ManagementAndGeneral>
        <Fundraising>12272</Fundraising>
      </CompCurrentOfficersDirectors>
      <OtherSalariesAndWages>
        <Total>1896493</Total>
        <ProgramServices>1216294</ProgramServices>
        <ManagementAndGeneral>596229</ManagementAndGeneral>
        <Fundraising>83970</Fundraising>
      </OtherSalariesAndWages>
      <OtherEmployeeBenefits>
        <Total>685469</Total>
        <ProgramServices>432264</ProgramServices>
        <ManagementAndGeneral>230252</ManagementAndGeneral>
        <Fundraising>22953</Fundraising>
      </OtherEmployeeBenefits>
      <PayrollTaxes>
        <Total>311927</Total>
        <ProgramServices>145086</ProgramServices>
        <ManagementAndGeneral>166841</ManagementAndGeneral>
      </PayrollTaxes>
      <FeesForServicesLegal>
        <Total>468002</Total>
        <ProgramServices>461245</ProgramServices>
        <ManagementAndGeneral>6757</ManagementAndGeneral>
      </FeesForServicesLegal>
      <FeesForServicesAccounting>
        <Total>57375</Total>
        <ManagementAndGeneral>57375</ManagementAndGeneral>
      </FeesForServicesAccounting>
      <Advertising>
        <Total>28040</Total>
        <ProgramServices>13960</ProgramServices>
        <ManagementAndGeneral>14080</ManagementAndGeneral>
      </Advertising>
      <OfficeExpenses>
        <Total>33251</Total>
        <ProgramServices>14327</ProgramServices>
        <ManagementAndGeneral>18710</ManagementAndGeneral>
        <Fundraising>214</Fundraising>
      </OfficeExpenses>
      <InformationTechnology>
        <Total>1193931</Total>
        <ProgramServices>1110552</ProgramServices>
        <ManagementAndGeneral>83379</ManagementAndGeneral>
      </InformationTechnology>
      <Occupancy>
        <Total>361991</Total>
        <ProgramServices>159541</ProgramServices>
        <ManagementAndGeneral>202450</ManagementAndGeneral>
      </Occupancy>
      <Travel>
        <Total>2464332</Total>
        <ProgramServices>2356907</ProgramServices>
        <ManagementAndGeneral>103013</ManagementAndGeneral>
        <Fundraising>4412</Fundraising>
      </Travel>
      <DepreciationDepletion>
        <Total>51982</Total>
        <ManagementAndGeneral>51982</ManagementAndGeneral>
      </DepreciationDepletion>
      <Insurance>
        <Total>170674</Total>
        <ProgramServices>125284</ProgramServices>
        <ManagementAndGeneral>45390</ManagementAndGeneral>
      </Insurance>
      <OtherExpenses>
        <Description>PROGRAM CONTRACTS</Description>
        <Total>10289121</Total>
        <ProgramServices>10289121</ProgramServices>
      </OtherExpenses>
      <OtherExpenses>
        <Description>CONSULTANTS</Description>
        <Total>3969517</Total>
        <ProgramServices>3871766</ProgramServices>
        <ManagementAndGeneral>97751</ManagementAndGeneral>
      </OtherExpenses>
      <OtherExpenses>
        <Description>PRINTING AND PHOTOCOPYI</Description>
        <Total>106636</Total>
        <ProgramServices>69880</ProgramServices>
        <ManagementAndGeneral>28285</ManagementAndGeneral>
        <Fundraising>8471</Fundraising>
      </OtherExpenses>
      <OtherExpenses>
        <Description>SERVICE CHARGES</Description>
        <Total>103406</Total>
        <ProgramServices>44196</ProgramServices>
        <ManagementAndGeneral>59210</ManagementAndGeneral>
      </OtherExpenses>
      <AllOtherExpenses>
        <Total>150653</Total>
        <ProgramServices>76200</ProgramServices>
        <ManagementAndGeneral>65401</ManagementAndGeneral>
        <Fundraising>9052</Fundraising>
      </AllOtherExpenses>
      <TotalFunctionalExpenses>
        <Total>50503879</Total>
        <ProgramServices>47575872</ProgramServices>
        <ManagementAndGeneral>2786663</ManagementAndGeneral>
        <Fundraising>141344</Fundraising>
      </TotalFunctionalExpenses>
      <SavingsAndTempCashInvestments>
        <BOY>40446083</BOY>
        <EOY>55108789</EOY>
      </SavingsAndTempCashInvestments>
      <PledgesAndGrantsReceivable>
        <BOY>22057687</BOY>
        <EOY>18080849</EOY>
      </PledgesAndGrantsReceivable>
      <PrepaidExpensesDeferredCharges>
        <BOY>83002</BOY>
        <EOY>102130</EOY>
      </PrepaidExpensesDeferredCharges>
      <LandBuildingsEquipmentBasis>589354</LandBuildingsEquipmentBasis>
      <LandBldgEquipmentAccumDeprec>483657</LandBldgEquipmentAccumDeprec>
      <LandBuildingsEquipmentBasisNet>
        <BOY>98438</BOY>
        <EOY>105697</EOY>
      </LandBuildingsEquipmentBasisNet>
      <InvestmentsOtherSecurities>
        <BOY>28605631</BOY>
        <EOY>24658302</EOY>
      </InvestmentsOtherSecurities>
      <TotalAssets>
        <BOY>91290841</BOY>
        <EOY>98055767</EOY>
      </TotalAssets>
      <AccountsPayableAccruedExpenses>
        <BOY>1252432</BOY>
        <EOY>2561263</EOY>
      </AccountsPayableAccruedExpenses>
      <DeferredRevenue>
        <BOY>14755033</BOY>
        <EOY>7862751</EOY>
      </DeferredRevenue>
      <EscrowAccountLiability>
        <BOY>1745257</BOY>
        <EOY>3198809</EOY>
      </EscrowAccountLiability>
      <TotalLiabilities>
        <BOY>17752722</BOY>
        <EOY>13622823</EOY>
      </TotalLiabilities>
      <FollowSFAS117>X</FollowSFAS117>
      <UnrestrictedNetAssets>
        <BOY>9103221</BOY>
        <EOY>10078788</EOY>
      </UnrestrictedNetAssets>
      <TemporarilyRestrictedNetAssets>
        <BOY>61126724</BOY>
        <EOY>71045848</EOY>
      </TemporarilyRestrictedNetAssets>
      <PermanentlyRestrictedNetAssets>
        <BOY>3308174</BOY>
        <EOY>3308308</EOY>
      </PermanentlyRestrictedNetAssets>
      <TotalNetAssetsFundBalances>
        <BOY>73538119</BOY>
        <EOY>84432944</EOY>
      </TotalNetAssetsFundBalances>
      <TotalLiabNetAssetsFundBalances>
        <BOY>91290841</BOY>
        <EOY>98055767</EOY>
      </TotalLiabNetAssetsFundBalances>
      <InfoInScheduleOPartXI>X</InfoInScheduleOPartXI>
      <ReconcilationRevenueExpenses>10946370</ReconcilationRevenueExpenses>
      <ReconcilationOtherChanges>-51545</ReconcilationOtherChanges>
      <InfoInScheduleOPartXII>X</InfoInScheduleOPartXII>
      <MethodOfAccountingAccrual>X</MethodOfAccountingAccrual>
      <AccountantCompileOrReview>0</AccountantCompileOrReview>
      <FSAudited>1</FSAudited>
      <AuditCommittee>1</AuditCommittee>
      <FinancialStatementSeparate>X</FinancialStatementSeparate>
      <FederalGrantAuditRequired>0</FederalGrantAuditRequired>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PubliclySupportedOrg170b1Avi>X</PubliclySupportedOrg170b1Avi>
      <GiftsGrantsContribReceived170>
        <CurrentTaxYearMinus4Years>56897459</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>81264504</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>71174551</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>63125631</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>59279254</CurrentTaxYear>
        <Total>331741399</Total>
      </GiftsGrantsContribReceived170>
      <ValueSrvcFcltsFurnishedByGovt>
        <CurrentTaxYearMinus4Years>587451</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>584653</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>503112</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>500000</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>486000</CurrentTaxYear>
        <Total>2661216</Total>
      </ValueSrvcFcltsFurnishedByGovt>
      <Total170>
        <CurrentTaxYearMinus4Years>57484910</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>81849157</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>71677663</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>63625631</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>59765254</CurrentTaxYear>
        <Total>334402615</Total>
      </Total170>
      <AmountsSubstContributorsTotal>170018519</AmountsSubstContributorsTotal>
      <PublicSupportTotal170>164384096</PublicSupportTotal170>
      <GrossInvestmentIncome170>
        <CurrentTaxYearMinus4Years>8171307</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>3698901</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>806143</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>173991</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>134140</CurrentTaxYear>
        <Total>12984482</Total>
      </GrossInvestmentIncome170>
      <TotalSupport>347387097</TotalSupport>
      <GrossReceiptsFromAdmissionsEtc>3058082</GrossReceiptsFromAdmissionsEtc>
      <PublicSupportPertcentage170>0.47320</PublicSupportPertcentage170>
      <PublicSupportPertcentPriorYear>0.64610</PublicSupportPertcentPriorYear>
      <ThirtyThreePercntTestsCY170>X</ThirtyThreePercntTestsCY170>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInfo>
        <ContributorNumber>RESTRICTED</ContributorNumber>
        <ContributorNameBusiness>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorNameBusiness>
        <ContributorAddressUS>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorAddressUS>
        <AggregateContributions>RESTRICTED</AggregateContributions>
      </ContributorInfo>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="RetDoc1039900001">
      <NumberDAFsHeld>2</NumberDAFsHeld>
      <DonorAdvisedContributions>480186</DonorAdvisedContributions>
      <GrantsPaidFromDonorFunds>1013301</GrantsPaidFromDonorFunds>
      <AggregateDAFValue>8116661</AggregateDAFValue>
      <DisclosedOrgsLegalControl>1</DisclosedOrgsLegalControl>
      <DisclosedForCharitablePurposes>1</DisclosedForCharitablePurposes>
      <AgentTrusteeEtc>0</AgentTrusteeEtc>
      <IncludedOnFS>1</IncludedOnFS>
      <CurrentYear>
        <BeginningOfYearBalance>3690564</BeginningOfYearBalance>
        <Contributions>3214</Contributions>
        <InvestmentEarningsOrLosses>-91</InvestmentEarningsOrLosses>
        <AdministrativeExpenses>63053</AdministrativeExpenses>
        <EndOfYearBalance>3630634</EndOfYearBalance>
      </CurrentYear>
      <CurrentYearMinus1Year>
        <BeginningOfYearBalance>3736712</BeginningOfYearBalance>
        <Contributions>9744</Contributions>
        <InvestmentEarningsOrLosses>23343</InvestmentEarningsOrLosses>
        <AdministrativeExpenses>79235</AdministrativeExpenses>
        <EndOfYearBalance>3690564</EndOfYearBalance>
      </CurrentYearMinus1Year>
      <CurrentYearMinus2Years>
        <BeginningOfYearBalance>3791493</BeginningOfYearBalance>
        <Contributions>20898</Contributions>
        <InvestmentEarningsOrLosses>48619</InvestmentEarningsOrLosses>
        <AdministrativeExpenses>124298</AdministrativeExpenses>
        <EndOfYearBalance>3736712</EndOfYearBalance>
      </CurrentYearMinus2Years>
      <CurrentYearMinus3Years>
        <BeginningOfYearBalance>3777493</BeginningOfYearBalance>
        <Contributions>10445</Contributions>
        <InvestmentEarningsOrLosses>104761</InvestmentEarningsOrLosses>
        <AdministrativeExpenses>101206</AdministrativeExpenses>
        <EndOfYearBalance>3791493</EndOfYearBalance>
      </CurrentYearMinus3Years>
      <PermanentEndowmentEOYBalance>0.91000</PermanentEndowmentEOYBalance>
      <TermEndowmentEOYBalance>0.09000</TermEndowmentEOYBalance>
      <EndowmentsHeldByUnrelatedOrgs>0</EndowmentsHeldByUnrelatedOrgs>
      <EndowmentsHeldByRelatedOrgs>0</EndowmentsHeldByRelatedOrgs>
      <Equipment>
        <OtherCostOrOtherBasis>441663</OtherCostOrOtherBasis>
        <Depreciation>359866</Depreciation>
        <BookValue>81797</BookValue>
      </Equipment>
      <OtherLandBuildings>
        <OtherCostOrOtherBasis>147691</OtherCostOrOtherBasis>
        <Depreciation>123791</Depreciation>
        <BookValue>23900</BookValue>
      </OtherLandBuildings>
      <TotalOfBookValueLandBuildings>105697</TotalOfBookValueLandBuildings>
      <OtherSecurities>
        <Description>DISCOUNT NOTES</Description>
        <BookValue>10491440</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>BOND MUTUAL FUNDS</Description>
        <BookValue>398377</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>EQUITY MUTUAL FUNDS</Description>
        <BookValue>162022</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>CORPORATE BONDS</Description>
        <BookValue>93114</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>GOVERNMENT BONDS</Description>
        <BookValue>12996930</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>STOCKS</Description>
        <BookValue>469857</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>REIT</Description>
        <BookValue>18461</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <OtherSecurities>
        <Description>EXCHANGE TRADED FUNDS</Description>
        <BookValue>28101</BookValue>
        <MethodOfValuation>F</MethodOfValuation>
      </OtherSecurities>
      <TotalOfBookValueSecurities>24658302</TotalOfBookValueSecurities>
      <TotalRevenue>61450249</TotalRevenue>
      <TotalExpenses>50503879</TotalExpenses>
      <ExcessOrDeficitForYear>10946370</ExcessOrDeficitForYear>
      <NetUnrealizedGLOnInvestments>-51545</NetUnrealizedGLOnInvestments>
      <TotalAdjustments>-51545</TotalAdjustments>
      <ExcessOrDeficitPerFS>10894825</ExcessOrDeficitPerFS>
      <TotRevenueEtcAuditedFinclStmt>63480862</TotRevenueEtcAuditedFinclStmt>
      <NetUnrealizedGainsInvestments>-51545</NetUnrealizedGainsInvestments>
      <DonatedSrvcAndUseOfFacilities>44892</DonatedSrvcAndUseOfFacilities>
      <OtherRevenues>2037266</OtherRevenues>
      <RevenueNotRptdF990>2030613</RevenueNotRptdF990>
      <RevenueSubtotal>61450249</RevenueSubtotal>
      <RevenueNotRptdOnFinStmt>0</RevenueNotRptdOnFinStmt>
      <TotalRevenuePerForm990>61450249</TotalRevenuePerForm990>
      <TotExpensesEtcAuditedFinclStmt>52586037</TotExpensesEtcAuditedFinclStmt>
      <DonatedServicesUseOfFacilities>44892</DonatedServicesUseOfFacilities>
      <OtherExpensesIncluded>2037266</OtherExpensesIncluded>
      <ExpensesNotRptdF990>2082158</ExpensesNotRptdF990>
      <ExpensesSubtotal>50503879</ExpensesSubtotal>
      <ExpensesNotRptdOnFinStmt>0</ExpensesNotRptdOnFinStmt>
      <TotalExpensesPerForm990>50503879</TotalExpensesPerForm990>
      <Form990ScheduleDPartXIV>
        <ReturnReference>PART IV, LINE 2B:</ReturnReference>
        <Explanation>AS OF 12/31/2011, THE FNIH HELD $3,198,809 IN AGENCY FUNDS FOR FUTURE DISTRIBUTION TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED.</Explanation>
      </Form990ScheduleDPartXIV>
      <Form990ScheduleDPartXIV>
        <Identifier>DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS:</Identifier>
        <ReturnReference>PART V, LINE 4:</ReturnReference>
        <Explanation>THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS.</Explanation>
      </Form990ScheduleDPartXIV>
      <Form990ScheduleDPartXIV>
        <Identifier>DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48:</Identifier>
        <ReturnReference>PART X:</ReturnReference>
        <Explanation>THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2011 AND 2010. FISCAL YEARS ENDING ON OR AFTER DECEMBER 31, 2008 REMAIN SUBJECT TO EXAMINATION BY FEDERAL AND STATE TAX AUTHORIES.</Explanation>
      </Form990ScheduleDPartXIV>
      <Form990ScheduleDPartXIV>
        <Identifier>PART XII, LINE 2D - OTHER ADJUSTMENTS:</Identifier>
        <Explanation>IN KIND CONTRIBUTIONS</Explanation>
      </Form990ScheduleDPartXIV>
      <Form990ScheduleDPartXIV>
        <Identifier>PART XIII, LINE 2D - OTHER ADJUSTMENTS:</Identifier>
        <Explanation>IN KIND CONTRIBUTIONS</Explanation>
      </Form990ScheduleDPartXIV>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintained>1</GrantRecordsMaintained>
      <AcctsActvsOutUSTable>
        <Region>EAST AISA &amp; THE PACIFIC</Region>
        <TypeOfActivitiesConducted>GRANTMAKING</TypeOfActivitiesConducted>
        <TotalExpenditures>4079819</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>EUROPE</Region>
        <TypeOfActivitiesConducted>GRANTMAKING</TypeOfActivitiesConducted>
        <TotalExpenditures>4391797</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>SUB-SAHARAN AFRICA</Region>
        <TypeOfActivitiesConducted>GRANTMAKING</TypeOfActivitiesConducted>
        <TotalExpenditures>277573</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>SOUTH ASIA</Region>
        <TypeOfActivitiesConducted>GRANTMAKING</TypeOfActivitiesConducted>
        <TotalExpenditures>933583</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <SubtotalNumberOfOffices>0</SubtotalNumberOfOffices>
      <SubtotalNumberOfEmployees>0</SubtotalNumberOfEmployees>
      <ContNumberOfOffices>0</ContNumberOfOffices>
      <ContNumberOfEmployees>0</ContNumberOfEmployees>
      <TotalNumberOfOffices>0</TotalNumberOfOffices>
      <TotalNumberOfEmployees>0</TotalNumberOfEmployees>
      <SubtotalAmountSpent>9682772</SubtotalAmountSpent>
      <ContAmountSpent>0</ContAmountSpent>
      <TotalAmountSpent>9682772</TotalAmountSpent>
      <NoRecipientOver5K>X</NoRecipientOver5K>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>DEVELOP A GENETIC STRATEGY TO DEPLETE OR INCAPACITATE INSECTS</PurposeOfGrant>
        <AmountOfCashGrant>2000000</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EAST ASIA AND THE PACIFIC</Region>
        <PurposeOfGrant>MODIFYING MOSQUITO POPULATION AGE STRUCTURE TO ELIMINATE DENGUE TRANSMISSION</PurposeOfGrant>
        <AmountOfCashGrant>733295</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>IMMUNE CORRELATES</PurposeOfGrant>
        <AmountOfCashGrant>115152</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>NON-HUMAN PRIMATE CORE</PurposeOfGrant>
        <AmountOfCashGrant>26884</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>SOUTH ASIA</Region>
        <PurposeOfGrant>MALNUTRITION AND ENTERIC DISEASES NETWORK</PurposeOfGrant>
        <AmountOfCashGrant>518070</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>SOUTH ASIA</Region>
        <PurposeOfGrant>MALNUTRITION AND ENTERIC DISEASES NETWORK</PurposeOfGrant>
        <AmountOfCashGrant>415513</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>IMMUNOGENICITY STUDY(CECI)</PurposeOfGrant>
        <AmountOfCashGrant>13333</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>DISTRIBUTED PARTNER IN METHODS/OMOP</PurposeOfGrant>
        <AmountOfCashGrant>33602</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>CREATE NEW VACCINES</PurposeOfGrant>
        <AmountOfCashGrant>1350000</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS</PurposeOfGrant>
        <AmountOfCashGrant>412095</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>SUB-SAHARAN AFRICA</Region>
        <PurposeOfGrant>IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS</PurposeOfGrant>
        <AmountOfCashGrant>277573</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EAST ASIA AND THE PACIFIC</Region>
        <PurposeOfGrant>MODIFYING MOSQUITO POPULATION AGE STRUCTURE TO ELIMINATE DENGUE TRANSMISSION</PurposeOfGrant>
        <AmountOfCashGrant>3346524</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS</PurposeOfGrant>
        <AmountOfCashGrant>372944</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>EUROPE</Region>
        <PurposeOfGrant>DETECTION OF LONG TERM ADVERSE DRUG REACTIONS IN ELECTRONIC HEALTH CARE DATA</PurposeOfGrant>
        <AmountOfCashGrant>67787</AmountOfCashGrant>
        <MannerOfCashDisbursement>WIRE TRANSFER</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <TotalNumberOf501c3Orgs>2</TotalNumberOf501c3Orgs>
      <TotalNumberOfOtherOrgs>12</TotalNumberOfOtherOrgs>
      <TransferToForeignCorp>0</TransferToForeignCorp>
      <InterestInForeignTrust>0</InterestInForeignTrust>
      <OwnForeignCorp>0</OwnForeignCorp>
      <PassiveForeignInvestCo>0</PassiveForeignInvestCo>
      <ForeignPartnership>0</ForeignPartnership>
      <BoycottCountries>0</BoycottCountries>
      <Form990ScheduleFPartV>
        <Identifier>PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.:</Identifier>
        <Explanation>SCHEDULE F, PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS.</Explanation>
      </Form990ScheduleFPartV>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <RecordsMaintained>1</RecordsMaintained>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>BETH ISRAEL DEACONESS MEDICAL CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>330 BROOKLINE AVENUE</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02215</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042103881</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>271769</AmountOfCashGrant>
        <PurposeOfGrant>NON HUMAN PRIMATE NEW ASSAY</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>CALIFORNIA PACIFIC MEDICAL CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>475 BRANNAN STREET SUITE 220</AddressLine1>
          <City>SAN FRANCISCO</City>
          <State>CA</State>
          <ZIPCode>94107</ZIPCode>
        </AddressUS>
        <EINOfRecipient>950562680</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>31500</AmountOfCashGrant>
        <PurposeOfGrant>SARCOPENIA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>CHICAGO ASSOCIATION FOR RESEARCH AND EDUCATION IN SCIENCE (CARES)</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>BUILDING ONE ROOM C347 5000 SOUTH</AddressLine1>
          <AddressLine2>5TH AVENUE</AddressLine2>
          <City>HINES</City>
          <State>IL</State>
          <ZIPCode>60141</ZIPCode>
        </AddressUS>
        <EINOfRecipient>363334177</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>119246</AmountOfCashGrant>
        <PurposeOfGrant>DISTRIBUTED RESEARCH PARTNER COLLABORATION WITH THE OMOP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>COLUMBIA UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>722 WEST 168TH ST 4TH FLOOR</AddressLine1>
          <City>NEW YORK</City>
          <State>NY</State>
          <ZIPCode>10032</ZIPCode>
        </AddressUS>
        <EINOfRecipient>135598093</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>91566</AmountOfCashGrant>
        <PurposeOfGrant>SARCOPENIA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DUKE UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>2200 WEST MAIN STREET SUITE 820</AddressLine1>
          <AddressLine2>ERWIN SQUARE PLAZA</AddressLine2>
          <City>DURHAM</City>
          <State>NC</State>
          <ZIPCode>27705</ZIPCode>
        </AddressUS>
        <EINOfRecipient>560532129</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>831108</AmountOfCashGrant>
        <PurposeOfGrant>PROFICIENCY TESTING CENTRAL/CECI</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>EMORY UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1599 CLIFTON ROAD NE 4TH FLOOR</AddressLine1>
          <City>ATLANTA</City>
          <State>GA</State>
          <ZIPCode>30322</ZIPCode>
        </AddressUS>
        <EINOfRecipient>580566256</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>43713</AmountOfCashGrant>
        <PurposeOfGrant>IMMUNOLOGICAL STRATEGIES FOR CURING CHRONIC HEPATITIS VIRUS INFECTIONS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>FRED HUTCHINSON CANCER RESEARCH CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1100 FAIRVIEW AVE N</AddressLine1>
          <City>SEATTLE</City>
          <State>WA</State>
          <ZIPCode>98109</ZIPCode>
        </AddressUS>
        <EINOfRecipient>237156071</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>277821</AmountOfCashGrant>
        <PurposeOfGrant>CLADE SPECIFIC T CELL RESPONSES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>HENRY JACKSON FOUNDATION (USMHRP )</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1401 ROCKVILLE PIKE SUITE 600</AddressLine1>
          <City>ROCKVILLE</City>
          <State>MD</State>
          <ZIPCode>20852</ZIPCode>
        </AddressUS>
        <EINOfRecipient>521317896</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>447090</AmountOfCashGrant>
        <PurposeOfGrant>PROFICIENCY TESTING/MAL-ED</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>HUMANA INC</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>500 WEST MAIN STREET</AddressLine1>
          <City>LOUISVILLE</City>
          <State>KY</State>
          <ZIPCode>20202</ZIPCode>
        </AddressUS>
        <EINOfRecipient>611383567</EINOfRecipient>
        <AmountOfCashGrant>240879</AmountOfCashGrant>
        <PurposeOfGrant>OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>615 N WOLFE ST W1100</AddressLine1>
          <City>BALTIMORE</City>
          <State>MD</State>
          <ZIPCode>21205</ZIPCode>
        </AddressUS>
        <EINOfRecipient>150595110</EINOfRecipient>
        <AmountOfCashGrant>1215607</AmountOfCashGrant>
        <PurposeOfGrant>MAL-ED</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>PARTNERS HEALTHCARE SYSTEM INC</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>ONE CONSTITUTION CENTER</AddressLine1>
          <City>CHARLESTOWN</City>
          <State>MA</State>
          <ZIPCode>02129</ZIPCode>
        </AddressUS>
        <EINOfRecipient>043230035</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>231556</AmountOfCashGrant>
        <PurposeOfGrant>OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>SDI HEALTH LLC</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>220 WEST GERMANTOWN PIKE</AddressLine1>
          <City>PLYMOUTH MEETING</City>
          <State>PA</State>
          <ZIPCode>19462</ZIPCode>
        </AddressUS>
        <EINOfRecipient>262863550</EINOfRecipient>
        <AmountOfCashGrant>217225</AmountOfCashGrant>
        <PurposeOfGrant>OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>SLIPPERY ROCK UNIVERSITY FOUNDATION</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>100 OLD MAIN 1 MORROW WAY</AddressLine1>
          <City>SLIPPERY ROCK</City>
          <State>PA</State>
          <ZIPCode>16057</ZIPCode>
        </AddressUS>
        <EINOfRecipient>251513539</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>6500</AmountOfCashGrant>
        <PurposeOfGrant>"ENHANCE PHYSICAL ACTIVITY, GOOD NUTRITION, FITNESS AND HEALTHY LIFESTYLES IN CHILDREN AND YOUTH DISABILITIES."</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>630 WEST 168TH STREET</AddressLine1>
          <City>NEW YORK</City>
          <State>NY</State>
          <ZIPCode>10032</ZIPCode>
        </AddressUS>
        <EINOfRecipient>135598093</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>1750000</AmountOfCashGrant>
        <PurposeOfGrant>MOLECULAR APPROACHES TO ALTER OLFACTORY-DRIVEN BEHAVIORS OF INSECT DISEASE VECTORS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 66057</AddressLine1>
          <City>INDIANAPOLIS</City>
          <State>IN</State>
          <ZIPCode>46266</ZIPCode>
        </AddressUS>
        <EINOfRecipient>356001673</EINOfRecipient>
        <AmountOfCashGrant>380486</AmountOfCashGrant>
        <PurposeOfGrant>OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF CALIFORNIA IRVINE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>300 UNIVERSITY TOWER</AddressLine1>
          <City>IRVINE</City>
          <State>CA</State>
          <ZIPCode>92697</ZIPCode>
        </AddressUS>
        <EINOfRecipient>952540117</EINOfRecipient>
        <AmountOfCashGrant>2000000</AmountOfCashGrant>
        <PurposeOfGrant>GENETIC STRATEGIES FOR CONTROL OF DENGUE VIRUS TRANSMISSION</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF MARYLAND BALTIMORE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 41428</AddressLine1>
          <City>MARYLAND</City>
          <State>MD</State>
          <ZIPCode>21203</ZIPCode>
        </AddressUS>
        <EINOfRecipient>311678679</EINOfRecipient>
        <AmountOfCashGrant>31500</AmountOfCashGrant>
        <PurposeOfGrant>SARCOPENIA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF VIRGINIA</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 400195</AddressLine1>
          <City>CHARLOTTESVILLE</City>
          <State>VA</State>
          <ZIPCode>22904</ZIPCode>
        </AddressUS>
        <EINOfRecipient>546001796</EINOfRecipient>
        <IRCSection>GOVERNMENT UNIT</IRCSection>
        <AmountOfCashGrant>1572625</AmountOfCashGrant>
        <PurposeOfGrant>MAL-ED</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>VACCINE AND GENE THERAPY INSTITUTE FLORIDA</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>11350 SW VILLAGE PARKWAY THIRD</AddressLine1>
          <AddressLine2>FLOOR</AddressLine2>
          <City>PORT ST LUCIE</City>
          <State>FL</State>
          <ZIPCode>34987</ZIPCode>
        </AddressUS>
        <EINOfRecipient>364631835</EINOfRecipient>
        <IRCSection>171(C)(1)</IRCSection>
        <AmountOfCashGrant>731440</AmountOfCashGrant>
        <PurposeOfGrant>VIMC/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>VANDERBILT UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>2301 VANDERLBILT PLACE</AddressLine1>
          <City>NASHVILLE</City>
          <State>TN</State>
          <ZIPCode>37235</ZIPCode>
        </AddressUS>
        <EINOfRecipient>620476822</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>1000000</AmountOfCashGrant>
        <PurposeOfGrant>DISRUPTION OF MALARIA TRANSMISSION/VECTOR</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>IAVI</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>110 WILLIAM STREET FLOOR 27</AddressLine1>
          <City>NEW YORK</City>
          <State>NY</State>
          <ZIPCode>10038</ZIPCode>
        </AddressUS>
        <EINOfRecipient>133870223</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>487481</AmountOfCashGrant>
        <PurposeOfGrant>CTV SCIENTIFIC CORE LABORATORIES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>NORTHEASTERN UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>360 HUNTINGTON AVE 960 RP</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>041679980</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>20000</AmountOfCashGrant>
        <PurposeOfGrant>SARCOPENIA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>TRUSTEES OF BOSTON UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>85 E NEWTON ST M-921</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02118</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042103547</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>660801</AmountOfCashGrant>
        <PurposeOfGrant>ILLUMINATING THE CELLULAR TROPISM OF MEASLES VACCINE VIRUSES IN MACAQUES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>AUBURN UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>310 SAMFORD HALL</AddressLine1>
          <City>AUBURN</City>
          <State>AL</State>
          <ZIPCode>36849</ZIPCode>
        </AddressUS>
        <EINOfRecipient>636000724</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>212850</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPING A STRUCTURED PROCESS FOR MEASURING AND INTERPRETING HEALTH OUTCOMES OF INTEREST IN THE OMOP COMMON DATA MODEL</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>CARDIOLOGY ASSOCIATES</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>405 SOUTHWEST DRIVE PMB</AddressLine1>
          <City>JONESBORO</City>
          <State>AR</State>
          <ZIPCode>72401</ZIPCode>
        </AddressUS>
        <EINOfRecipient>200213310</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>27250</AmountOfCashGrant>
        <PurposeOfGrant>HEART TRUTH</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>COLORADO STATE UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>601 HOWES STREET</AddressLine1>
          <City>FORT COLLINS</City>
          <State>CO</State>
          <ZIPCode>80523</ZIPCode>
        </AddressUS>
        <IRCSection>170(C)(1)</IRCSection>
        <AmountOfCashGrant>466830</AmountOfCashGrant>
        <PurposeOfGrant>MOLECULAR MOSQUITOCIDES: DEVELOPMENT OF AN INNOVATICE AND ROBUST, PLATFORM-BASED APPROACH FOR SUSTAINABLE INSECTICIDAL CONTROL OF ANOPHELINE MOSQUITOES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>COMMUNITY HEALTH</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>225 MEMORIAL DRIVE</AddressLine1>
          <City>BERLIN</City>
          <State>WI</State>
          <ZIPCode>54923</ZIPCode>
        </AddressUS>
        <EINOfRecipient>731639346</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>25100</AmountOfCashGrant>
        <PurposeOfGrant>HEART TRUTH</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>COVENANT HEALTH</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1921 TOPSIDE ROAD SUITE 100</AddressLine1>
          <City>LOUISVILLE</City>
          <State>TN</State>
          <ZIPCode>37777</ZIPCode>
        </AddressUS>
        <EINOfRecipient>621646734</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>29700</AmountOfCashGrant>
        <PurposeOfGrant>KNOW YOUR SIX, CHICK</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>55 FRUIT STREET</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02114</ZIPCode>
        </AddressUS>
        <EINOfRecipient>041564655</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>131800</AmountOfCashGrant>
        <PurposeOfGrant>OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>NIH-FIC</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>16 CENTER DRIVE</AddressLine1>
          <City>BETHESDA</City>
          <State>MD</State>
          <ZIPCode>20892</ZIPCode>
        </AddressUS>
        <EINOfRecipient>520858115</EINOfRecipient>
        <IRCSection>170(C)(1)</IRCSection>
        <AmountOfCashGrant>355353</AmountOfCashGrant>
        <PurposeOfGrant>MAL-ED</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>SWAT EMPOWERMENT</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 796</AddressLine1>
          <City>SPARTA</City>
          <State>GA</State>
          <ZIPCode>31087</ZIPCode>
        </AddressUS>
        <EINOfRecipient>651178033</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>30000</AmountOfCashGrant>
        <PurposeOfGrant>HEART TRUTH</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>THE OHIO STATE UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1960 KENNY RD</AddressLine1>
          <City>COLOMBUS</City>
          <State>OH</State>
          <ZIPCode>43210</ZIPCode>
        </AddressUS>
        <EINOfRecipient>316025986</EINOfRecipient>
        <IRCSection>170(C)(1)</IRCSection>
        <AmountOfCashGrant>466522</AmountOfCashGrant>
        <PurposeOfGrant>HIGH THROUGHPUT DISCOVERY OF CHEMICALS THAT INDUCE 'KIDNEY' FAILURE IN THE MALARIAL VECTOR ANOPHELES GAMBIAE</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>THE HOPE HEART INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1380 112TH AVE NE</AddressLine1>
          <City>BELLEVUE</City>
          <State>WA</State>
          <ZIPCode>98004</ZIPCode>
        </AddressUS>
        <EINOfRecipient>911138000</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>29555</AmountOfCashGrant>
        <PurposeOfGrant>HEART TRUTH</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF FLORIDA BOARD OF TRUSTEES</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 115500</AddressLine1>
          <City>GAINESVILLE</City>
          <State>FL</State>
          <ZIPCode>23611</ZIPCode>
        </AddressUS>
        <EINOfRecipient>596002052</EINOfRecipient>
        <IRCSection>170(C)(1)</IRCSection>
        <AmountOfCashGrant>463018</AmountOfCashGrant>
        <PurposeOfGrant>VOLTAGE-SENSITIVE POTASSIUM CHANNEL AS NEW TARGET FOR MOSQUITOCIDES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UCLA</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>405 HILGARD AVENUE</AddressLine1>
          <City>LOS ANGELES</City>
          <State>CA</State>
          <ZIPCode>90095</ZIPCode>
        </AddressUS>
        <IRCSection>GOVERNMENT UNIT</IRCSection>
        <AmountOfCashGrant>62303</AmountOfCashGrant>
        <PurposeOfGrant>HIGH PERFORMANCE STATISTICAL INFERENCE FOR OMOP</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>VESTARON CORPORATION</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>4717 CAMPUS DRIVE SUITE 1200</AddressLine1>
          <City>KALAMAZOO</City>
          <State>MI</State>
          <ZIPCode>49008</ZIPCode>
        </AddressUS>
        <EINOfRecipient>203831543</EINOfRecipient>
        <AmountOfCashGrant>498881</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF SYNTHETIC CHEMICAL MIMICS OF SELECTIVELY INSECTICIDAL NATURAL PEPTIDES</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>WHEATON FRANCISCAN HEALTHCARE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>400 W RIVER WOOD PARKWAY</AddressLine1>
          <City>GLENDALE</City>
          <State>WI</State>
          <ZIPCode>53212</ZIPCode>
        </AddressUS>
        <EINOfRecipient>391636804</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>21515</AmountOfCashGrant>
        <PurposeOfGrant>HEART TRUTH</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>YMCA MIDDLE RIO</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>210 TRUMAN ST NE SUITE A</AddressLine1>
          <City>ALBUQUERQUE</City>
          <State>NM</State>
          <ZIPCode>49008</ZIPCode>
        </AddressUS>
        <EINOfRecipient>850107101</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>30000</AmountOfCashGrant>
        <PurposeOfGrant>WOMEN'S HEALTH EQUITY</PurposeOfGrant>
      </RecipientTable>
      <TotalNbrOf501C3AndGovtGrants>27</TotalNbrOf501C3AndGovtGrants>
      <TotalNbrOfOtherOrganizations>15</TotalNbrOfOtherOrganizations>
      <Form990ScheduleIPartIII>
        <TypeOfGrant>AWARDS</TypeOfGrant>
        <NumberOfRecipients>42</NumberOfRecipients>
        <AmountOfCashGrant>265750</AmountOfCashGrant>
      </Form990ScheduleIPartIII>
      <Form990ScheduleIPartIV>
        <Identifier>PROCEDURE FOR MONITORING GRANTS IN THE U.S.:</Identifier>
        <ReturnReference>PART I, LINE 2:</ReturnReference>
        <Explanation>SCHEDULE I, PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE.</Explanation>
      </Form990ScheduleIPartIV>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <IndependentConsultant>X</IndependentConsultant>
      <WrittenEmploymentContract>X</WrittenEmploymentContract>
      <CompensationSurvey>X</CompensationSurvey>
      <BoardOrCommitteeApproval>X</BoardOrCommitteeApproval>
      <SeverancePayment>0</SeverancePayment>
      <SupplementalNonqualRetirePlan>0</SupplementalNonqualRetirePlan>
      <EquityBasedCompArrangement>0</EquityBasedCompArrangement>
      <CompBasedOnRevenueOfFilingOrg>0</CompBasedOnRevenueOfFilingOrg>
      <CompBasedOnRevenueRelatedOrgs>0</CompBasedOnRevenueRelatedOrgs>
      <CompBasedNetEarningsFilingOrg>0</CompBasedNetEarningsFilingOrg>
      <CompBasedNetEarningsRelateOrgs>0</CompBasedNetEarningsRelateOrgs>
      <AnyNonFixedPayments>0</AnyNonFixedPayments>
      <InitialContractException>0</InitialContractException>
      <Form990ScheduleJPartII>
        <NamePerson>SCOTT CAMPBELL</NamePerson>
        <BaseCompensationFilingOrg>222288</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>26825</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>22229</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>4596</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>249113</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>26825</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>DAVID WHOLLEY</NamePerson>
        <BaseCompensationFilingOrg>254463</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>3960</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>35802</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>25842</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>294225</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>35802</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>STEPHANIE JAMES</NamePerson>
        <BaseCompensationFilingOrg>261148</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>26115</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>26115</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>287263</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>26115</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>ANDREA BARUCHIN</NamePerson>
        <BaseCompensationFilingOrg>182310</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>200</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>22847</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>18251</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>4596</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>205357</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>22847</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>RICHARD SCARFO</NamePerson>
        <BaseCompensationFilingOrg>165114</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>26471</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>16511</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>191585</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>26471</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>JULIE TUNE</NamePerson>
        <BaseCompensationFilingOrg>167643</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>500</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>26774</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>16814</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>194917</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>26774</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>ANN ASHBY</NamePerson>
        <BaseCompensationFilingOrg>192466</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>720</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>29279</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>19319</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>222465</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>29279</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>JULIE WOLF-RODDA</NamePerson>
        <BaseCompensationFilingOrg>171808</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>27141</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>17181</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>198949</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>27141</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>MICHAEL GOTTLIEB</NamePerson>
        <BaseCompensationFilingOrg>214468</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>21447</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>21447</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>235915</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>21447</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>JUDITH SIUCIAK</NamePerson>
        <BaseCompensationFilingOrg>144270</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>600</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>24447</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>14487</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>169317</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>24447</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>GAIL LEVINE</NamePerson>
        <BaseCompensationFilingOrg>132905</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>3800</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>23631</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>13671</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>9960</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>160336</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>23631</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
    </IRS990ScheduleJ>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <GeneralExplanation>
        <Identifier>STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENT</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:</ReturnReference>
        <Explanation>THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY CONGRESS TO SUPPORT THE MISSION OF THE NATIONAL INSTITUTES OF HEALTH: IMPROVING HEALTH THROUGH SCIENTIFIC DISCOVERY. THE FOUNDATION IS A LEADER IN IDENTIFYING AND ADDRESSING COMPLEX SCIENTIFIC AND HEALTH ISSUES. IT IDENTIFIES AND DEVELOPS INNOVATIVE PUBLIC-PRIVATE PARTNERSHIPS WITH INDUSTRY, ACADEMIA, FOUNDATIONS, ASSOCIATIONS, AND INDIVIDUALS FOR BIOMEDICAL RESEARCH, EDUCATION AND TRAINING.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>PROGRAM ONE: RESEARCH PARTNERSHIPS</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS:</ReturnReference>
        <Explanation>FROM FUNDAMENTAL SCIENCE THAT PEERS DEEP INTO THE RECESSES OF CELLS TO CLINICAL TRIALS THAT CONFIRM THE SAFETY AND EFFICACY OF NEW PATIENT THERAPIES, THE FNIH CREATES PARTNERSHIPS THAT ADDRESS THE WORLD'S MOST PRESSING BIOMEDICAL CHALLENGES. FORMING COLLABORATIONS UNIQUELY SUITED TO THE TASK AT HAND, THE FOUNDATION CAN FIND WAYS TO SUPPORT RESEARCH INTO BASIC BIOCHEMICAL PROCESSES AS WELL AS DISEASES OF GLOBAL EPIDEMIC PROPORTION. EMBRACING AN EVER WIDER UNIVERSE OF PARTNERS, THE FNIH IS HELPING THE NIH TO INFORM NOT ONLY MEDICAL SCIENCE, BUT REGULATORY AND POLICY-MAKING AGENCIES THAT DIRECTLY IMPACT HEALTH CARE DELIVERY. KEY INITIATIVES IN GLOBAL HEALTH GRAND CHALLENGES IN GLOBAL HEALTH THE GRAND CHALLENGES IN GLOBAL HEALTH (GCGH) INITIATIVE ENCOURAGES SCIENTISTS FROM AROUND THE WORLD TO ADDRESS AND OVERCOME SOME OF THE OBSTACLES THAT BLOCK PROGRESS AGAINST DISEASES THAT AFFECT POPULATIONS IN THE DEVELOPING WORLD. GCGH REPRESENTS A MAJOR MILESTONE IN THE DEVELOPMENT OF THE FNIH. ESTABLISHED WITH THE BILL &amp; MELINDA GATES FOUNDATION IN 2003, THE PARTNERSHIP NOT ONLY INTRODUCED THE LARGEST GRANT MADE TO DATE TO THE FNIH, BUT IT CHALLENGED THE FNIH TO BROADEN ITS SUPPORT OF PARTNERSHIPS THROUGH FUNCTIONS WELL BEYOND FUNDRAISING. BY 2005, ADDITIONAL PARTNERS INCLUDED THE WELLCOME TRUST AND THE CANADIAN INSTITUTES OF HEALTH RESEARCH. THE FNIH ASSUMED ONGOING RESPONSIBILITY FOR BOTH THE SCIENTIFIC AND FINANCIAL OVERSIGHT OF 20 OF THE ORIGINAL 43 GCGH PROJECTS, OPERATING IN 25 COUNTRIES. FNIH-SUPPORTED INVESTIGATORS WORKED TO: - IMPROVE UPON EXISTING VACCINES SO AS NOT TO REQUIRE REFRIGERATION OR ADMINISTRATION BY NEEDLE; - ADVANCE VACCINE DEVELOPMENT THROUGH DESIGN OF MORE PROTECTIVE ANTIGENS; - DEVELOP BIOLOGIC, GENETIC AND CHEMICAL STRATEGIES TO CONTROL DISEASE TRANSMISSION BY INSECT VECTORS; - DEVELOP DRUGS AND DELIVERY SYSTEMS THAT MINIMIZE THE LIKELIHOOD OF RESISTANCE; AND - CREATE IMMUNOLOGICAL METHODS TO CURE CHRONIC INFECTIONS. VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVERY RESEARCH MOSQUITO-BORNE DISEASES KILL MILLIONS OF PEOPLE EVERY YEAR. DESPITE RECENT GAINS IN ITS CONTROL, MALARIA REMAINS THE BIGGEST KILLER; AT THE SAME TIME THE INCIDENCE OF DENGUE IS INCREASING DRAMATICALLY AROUND THE WORLD. ABSENT EFFECTIVE VACCINES, PREVENTION STRATEGIES HAVE FOCUSED LARGELY ON CONTROLLING MOSQUITO POPULATIONS AND INHIBITING DISEASE TRANSMISSION TO HUMANS. HOWEVER, AS MOSQUITOES DEVELOP RESISTANCE TO INSECTICIDES, EXISTING APPROACHES ARE NOT ENOUGH. FUNDED BY THE BILL &amp; MELINDA GATES FOUNDATION, THE VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVERY RESEARCH (VCTR) INITIATIVE IS MANAGED BY THE FNIH. IT BUILDS ON THE PROMISING GRAND CHALLENGES IN GLOBAL HEALTH RESEARCH INTO DEPLETING AND/OR INCAPACITATING DISEASE-TRANSMITTING MOSQUITOES. IT HAS THREE AREAS OF FOCUS: - COST-EFFECTIVE AND LONG-LASTING BIOLOGICAL CONTROL METHODS - REPELLENTS OR ATTRACTANTS THAT EXPLOIT OR DISRUPT THE MOSQUITO S ODOR RECEPTORS - SAFER, MORE EFFECTIVE, AND LESS EXPENSIVE INSECTICIDES COMPREHENSIVE T CELL VACCINE IMMUNE MONITORING CONSORTIUM AS THE RESEARCH COMMUNITY HAS COME TO RECOGNIZE THAT THE MOST EFFICIENT WAY TO OVERCOME THE DIFFICULT PROBLEM OF CREATING AN AIDS VACCINE IS THROUGH COLLABORATION AND THE SHARING OF INFORMATION, TOOLS AND MATERIALS, THE FNIH HAS PLAYED A KEY ROLE IN FACILITATING PARTNERSHIPS AMONG LEADING HIV/AIDS RESEARCHERS THROUGH SEVERAL COLLABORATIVE PROJECTS. THE BILL &amp; MELINDA GATES ESTABLISHED THE COLLABORATION FOR AIDS VACCINE DISCOVERY (CAVD TO BRING THE "BIG SCIENCE" APPROACH USED TO SEQUENCE THE HUMAN GENOME TO BEAR ON THE SCOURGE OF HIV/AIDS. IN 2005, THE FNIH PARTNERED WITH DR. RICHARD KOUP, CHIEF OF THE IMMUNOLOGY LAB AT THE VACCINE RESEARCH CENTER (VRC) AT THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, TO ESTABLISH THE COMPREHENSIVE T CELL VACCINE IMMUNE MONITORING CONSORTIUM (CTC- VIMC), A COLLABORATION AMONG LEADING HIV T CELL IMMUNOLOGISTS WHO WOULD WORK TO STANDARDIZE CELLULAR IMMUNOLOGICAL METHODS FOR MONITORING HIV VACCINE TRIALS IN HUMANS AND NON-HUMAN PRIMATES. THE INITIAL 5-YEAR PROJECT WAS THE LARGEST OF THE 26 CAVD AWARDS: $33 MILLION TO SUPPORT THE WORK OF 19 INTERNATIONAL INVESTIGATORS IN 14 INSTITUTIONS. THE CTC-VIMC RECEIVED A SUPPLEMENT OF $16.8 MILLION TO 2016 TO CONTINUE ITS SUCCESSFUL SUPPORT OF THE CAVD AS A CENTRAL SERVICE FACILITY. CENTRALIZED ENVELOPE COMPARATIVE IMMUNOGENICITY PHASE 1 TRIAL THE CENTRALIZED ENVELOPE COMPARATIVE IMMUNOGENICITY PHASE 1 TRIAL (CECI) IS ANOTHER COLLABORATION FOR AIDS VACCINE DISCOVERY (CAVD) PROGRAM ADMINISTERED BY THE FNIH. THE PROJECT FOCUSES ON CLINICAL TESTING OF A NOVEL VACCINE DEVELOPED THROUGH THE USE OF COMPUTATIONAL BIOLOGY TO OVERCOME THE VACCINE-DEVELOPMENT CHALLENGES ARISING FROM THE GENETIC DIVERSITY OF THE HIV VIRUS. APPROVED IN NOVEMBER 2009, THIS $6 MILLION PROJECT BRINGS TOGETHER A NEW MIX OF INVESTIGATORS AND INSTITUTIONS, INCLUDING MANY MAJOR STAKEHOLDERS OF THE GLOBAL HIV/ AIDS VACCINE INITIATIVE: THE CAVD, THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), THE NIAID-SUPPORTED CENTER FOR HIV/AIDS VACCINE IMMUNOLOGY (CHAVI), THE HIV VACCINE TESTING NETWORK (HVTN), AS WELL AS THE VACCINE RESEARCH CENTER, EUROVACC AND SANOFI-PASTEUR. DEVELOPMENT OF A SECOND GENERATION BROADLY NEUTRALIZING ANTIBODY PRODUCT TO PREVENT HIV-1 INFECTION STUDY BY LEADING RESEARCHERS, INCLUDING SEVERAL AT THE VACCINE RESEARCH CENTER (VRC) OF "NON- PROGRESSORS" - THOSE RARE INDIVIDUALS INFECTED WITH HIV WHO DO NOT BECOME SICK - HAS POINTED TO THE ROLE OF BROADLY NEUTRALIZING ANTIBODIES IN HALTING DISEASE PROGRESSION TO FULL-BLOWN AIDS. THE DEVELOPMENT OF A SECOND GENERATION BROADLY NEUTRALIZING ANTIBODY PRODUCT TO PREVENT HIV-1 INFECTION IS A FIVE-YEAR, $1.8 MILLION EFFORT TO HARNESS ONE SUCH ANTIBODY TO BETTER UNDERSTAND THIS PHENOMENON AND PRODUCE NEW TOOLS FOR THE FIGHT AGAINST AIDS. ITS AIM IS TO ENHANCE THE POTENCY, EFFICACY AND EVENTUAL CLINICAL UTILITY OF THE VRC01 MONOCLONAL ANTIBODY THROUGH GENETIC MODIFICATION. IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS THE HIT-TB PROJECT, LAUNCHED IN 2010, IS AN FNIH PARTNERSHIP WITH THE BILL &amp; MELINDA GATES FOUNDATION AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, ALONG WITH THE UNIVERSITIES OF CAPE TOWN, CAMBRIDGE AND DUNDEE. NEGOTIATIONS ARE UNDERWAY WITH POTENTIAL ADDITIONAL PHARMACEUTICAL COMPANY PARTNERS. THIS PROJECT SUPPORTS HIGH-THROUGHPUT SCREENING OF WHOLE MYCOBACTERIUM TUBERCULOSIS BACTERIA USING A CHEMICAL LIBRARY OF DIVERSE, HIGH-QUALITY MOLECULES. THE GOAL IS TO IDENTIFY A SERIES OF WELL-CHARACTERIZED SMALL MOLECULES WITH DEFINED, TRACTABLE BACTERIAL TARGETS, WHICH POTENTIALLY COULD BE DEVELOPED INTO DRUGS AGAINST TUBERCULOSIS MALNUTRITION AND ENTERIC DISEASES NETWORK THE MALNUTRITION AND ENTERIC DISEASES NETWORK (MAL-ED) PROJECT, LAUNCHED IN LATE 2008, IS AN FNIH PARTNERSHIP WITH THE BILL &amp; MELINDA GATES FOUNDATION AND IS CO-LED BY THE NIH'S FOGARTY INTERNATIONAL CENTER AND FNIH. MAL-ED SUPPORTS A NUMBER OF U.S. ACADEMIC AND INTERNATIONALLY BASED INSTITUTIONS AND THE U.S. AND THAI MILITARIES TO FORM A NETWORK OF EIGHT FIELD SITES IN THE DEVELOPING WORLD THAT FOCUS ON POPULATIONS WITH HIGH LEVELS OF MALNUTRITION AND ENTERIC INFECTIONS. MAL-ED SEEKS TO IMPROVE UNDERSTANDING OF THE COMPLEX INTERRELATIONSHIP BETWEEN ENTERIC INFECTIONS AND MALNUTRITION AND TO DESCRIBE ITS COMPOUNDING EFFECTS ON GROWTH, ON IMMUNE RESPONSIVENESS TO ORALLY ADMINISTERED VACCINES AND ON COGNITIVE DEVELOPMENT IN YOUNG CHILDREN IN RESOURCE-POOR ENVIRONMENTS. ONE OF THE PROJECT GOALS IS TO IDENTIFY VULNERABLE PERIODS IN EARLY LIFE, AND WITH THIS KNOWLEDGE DESIGN BETTER INTERVENTION STRATEGIES TO LIMIT THE RISK OF MORTALITY AND MORBIDITY IN CHILDREN. APPROXIMATELY 2,000 CHILDREN HAVE BEEN ENROLLED AT BIRTH AND ARE BEING CLOSELY FOLLOWED UNTIL AT LEAST TWO YEARS OF AGE. THE NETWORK IS PART OF A CONSORTIUM OF AFFILIATED GATES FOUNDATION-FUNDED PROJECTS. ALTHOUGH THESE PROJECTS ARE NOT DIRECTLY MANAGED BY THE FNIH, THEY BENEFIT FROM COLLABORATING WITH MAL-ED INVESTIGATORS AND BY HAVING ACCESS TO MAL-ED RESOURCES, DATA AND SAMPLES. THESE COMPANION PROJECTS SEEK TO IDENTIFY GENETIC MARKERS OF SUSCEPTIBILITY TO CHILDHOOD MALNUTRITION, TO ESTABLISH THE ROLE OF THE GUT MICROBIOME IN MALNUTRITION AND SUSCEPTIBILITY TO ENTERIC INFECTION, AND TO IDENTIFY FACTORS INVOLVED IN CHILDREN'S POOR IMMUNE RESPONSIVENESS TO ORAL POLIO AND ROTAVIRUS VACCINES IN THE DEVELOPING WORLD.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Explanation>OTHER KEY RESEARCH INITIATIVES THE BIOMARKERS CONSORTIUM FIVE YEARS SINCE ITS FORMATION, THE BIOMARKERS CONSORTIUM HAS HAD A MAJOR IMPACT ON ADVANCING BIOMARKERS AS TOOLS FOR IMPROVING MEDICINE, HAVING LAUNCHED 14 PROJECTS WORTH OVER $45 MILLION. CONSORTIUM PROJECTS FOCUS ON CLINICAL APPLICATION AND REGULATORY QUALIFICATION OF BIOMARKERS, WHICH ALLOWS THEIR PRACTICAL APPLICATION IN STREAMLINING THE DEVELOPMENT OF NEW TREATMENTS AND PROVIDING MORE EFFECTIVE PATIENT CARE IN 2011, THE BIOMARKERS CONSORTIUM: - COMPLETED ITS ALZHEIMER'S DISEASE PLASMA PROTEOMICS PROJECT. THIS PROJECT UTILIZED BLOOD SAMPLES FROM THE GROUNDBREAKING ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE TO QUALIFY BIOMARKERS USEFUL IN DIAGNOSING AND MONITORING PATIENTS; - SUBMITTED INTERIM RECOMMENDATIONS TO THE FDA FOR MEASURING CLINICAL OUTCOMES OF TREATMENTS FOR TWO COMMON TYPES OF INFECTION, COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) AND ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI). IT ALSO APPROVED THE LAUNCH OF THE SECOND PHASE OF THIS PROJECT, WHICH WILL SEEK TO DEVELOP NEW TOOLS TO MEASURE THESE OUTCOMES FOR USE IN CLINICAL TRIALS; - INITIATED QUALIFICATION WITH THE FDA OF FDG- PET AND VOLUMETRIC CT IMAGING AS MARKERS FOR DISEASE PROGRESSION AND RESPONSE TO THERAPY IN NON-HODGKIN'S LYMPHOMA AND NON-SMALL CELL LUNG CANCER. THIS EFFORT IS MAKING USE OF DATA FROM TWO, FIVE-YEAR CLINICAL STUDIES MANAGED BY THE NATIONAL CANCER INSTITUTE AND FUNDED THROUGH THE CONSORTIUM; - LAUNCHED THE BETA CELL MASS AND FUNCTION PROJECT, WHICH IS AN EFFORT TO STANDARDIZE METHODS THAT MEASURE PANCREATIC BETA CELL FUNCTION AND OPEN THE DOOR TO THE DEVELOPMENT OF NEW TREATMENTS FOR DIABETES. THE ABILITY TO TRACK THE PERFORMANCE OF THESE INSULIN-PRODUCING CELLS SHOULD ALLOW FOR BETTER DETECTION AND MONITORING OF THE PROGRESSION OF DIABETES; AND - LAUNCHED THE KIDNEY SAFETY BIOMARKERS PROJECT, A MAJOR COLLABORATION WITH THE CRITICAL PATH INSTITUTE TO QUALIFY NEW URINARY BIOMARKERS OF ACUTE DRUG-INDUCED KIDNEY INJURY, ENABLING MORE EFFICIENT DEVELOPMENT OF SAFER DRUGS FOR A BROAD RANGE OF DISEASES. OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP THE OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP'S (OMOP) MISSION IS TO INFORM THE IMPLEMENTATION OF A SYSTEMATIC MEDICAL PRODUCT SURVEILLANCE SYSTEM WITH EMPIRICAL EVIDENCE OF THE APPROPRIATE METHODS, DATA AND INFRASTRUCTURE NECESSARY TO IDENTIFY AND TRACK POTENTIAL RELEVANT SAFETY ISSUES. OMOP IS ONE OF THE MOST AMBITIOUS INITIATIVES IN THE FIELD, WHOSE RESEARCH AGENDA IS ADDRESSING DATA, METHODS, INFRASTRUCTURE AND GOVERNANCE QUESTIONS IN AN OPEN, SCIENTIFIC COLLABORATION. NOW ENTERING ITS FOURTH YEAR OF OPERATIONS, THE EFFORT CONTINUES TO BUILD UPON ITS EXISTING RESEARCH BASE BY ADVANCING METHODOLOGICAL RESEARCH, SUSTAINING AND IMPROVING THE ACCESSIBILITY AND FRAMEWORK OF THE OMOP RESEARCH LAB, AND ENHANCING AND EXPANDING OMOP'S TOOLS AND CAPABILITIES. ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE EIGHT YEARS AFTER ITS INITIAL LAUNCH, THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) HAS PRODUCED NUMEROUS ADJUNCT AND FOLLOW-UP STUDIES THAT ARE NOT ONLY ADVANCING UNDERSTANDING OF THIS DEVASTATING DISEASE, BUT CHANGING THE WAY SCIENTIFIC RESEARCH IS CONDUCTED WORLDWIDE. THE PROGRAM WAS CONCEIVED BY THE NATIONAL INSTITUTE ON AGING WHICH PROVIDES THE PUBLIC SUPPORT, AND THE FNIH PROVIDING SUPPORT FROM THE PRIVATE PARTNERS, WITH THE GOAL OF ENCOURAGING COLLABORATION BY A WIDE ARRAY OF RESEARCHERS IN ACADEMIA AND INDUSTRY. TO DO THAT, THE INITIATIVE HAD TO FIRST SOLVE THE PROBLEM OF STANDARDIZING COLLECTION OF DIFFERENT TYPES OF RESEARCH DATA. IT ESTABLISHED DETAILED PROTOCOLS FOR ENROLLING PATIENTS IN THE STUDY AND FOR COLLECTING AND ASSESSING THE CLINICAL/NEUROPSYCHOLOGICAL, NEUROIMAGING, AND OTHER BIOMARKER TESTS AND MEASURES USED TO TRACK DISEASE PROGRESSION OVER TIME. NEXT, IT CREATED AN OPEN DATABASE, WHERE DATA COULD BE UPLOADED AND DOWNLOADED AS THEY WERE GENERATED. THIS ENABLED RESEARCHERS AROUND THE WORLD TO ACCESS, SHARE AND COMPARE DATA AND FINDINGS QUICKLY, EVEN BEFORE PUBLICATION OF PAPERS. THE NET EFFECT IS A SIGNIFICANT ACCELERATION OF CRITICAL, AND OTHERWISE EXPENSIVE, RESEARCH. SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY WHILE THE INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS INCREASING SHARPLY IN THE U.S., A CURE REMAINS OUT OF REACH FOR THIS PROGRESSIVE AND DEBILITATING CONDITION. THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY (SPIROMICS) IS LAYING THE GROUNDWORK FOR CLINICAL TRIALS THAT COULD SPEED DEVELOPMENT OF EFFECTIVE THERAPIES. SUPPORTED BY THE FNIH AND SIX PRIVATE SECTOR PARTNERS, NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI) IS COLLECTING AND POOLING LUNG FUNCTION, IMAGING AND BIOCHEMICAL DATA FROM MORE THAN 3,000 COPD SUFFERERS AND CONTROLS OVER THREE YEARS. THESE DATA WILL ALLOW SCIENTISTS TO BETTER CATEGORIZE PATIENTS ACCORDING TO THEIR SPECIFIC COPD PROFILE, WHICH IN TURN SHOULD HELP THEM TAILOR POTENTIAL THERAPIES TO THOSE MOST LIKELY TO BENEFIT. RESEARCH PARTNERSHIP IN COGNITIVE AGING SCIENTISTS THROUGHOUT THE COUNTRY MET IN OCTOBER 2011 TO DISCUSS THEIR LATEST FINDINGS ON CHANGES IN BRAIN FUNCTION AND BEHAVIOR ASSOCIATED WITH NORMAL AGING. THE RESEARCHERS ARE GRANT RECIPIENTS FROM THE RESEARCH PARTNERSHIP IN COGNITIVE AGING, AN FNIH INITIATIVE WITH THE NATIONAL INSTITUTE ON AGING AND THE MCKNIGHT BRAIN RESEARCH FOUNDATION. THE PROGRAM AIMS TO EXPAND UNDERSTANDING OF HOW PEOPLE THINK, LEARN AND REMEMBER WITH AGE, AND TO DEVELOP INTERVENTIONS TO MAINTAIN COGNITIVE HEALTH AS THEY GROW OLDER. ALTOGETHER, THE $28 MILLION PARTNERSHIP IS FUNDING 17 DIFFERENT RESEARCH PROJECTS OVER THE COURSE OF FIVE YEARS.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>PROGRAM TWO: FELLOWSHIPS AND TRAINING PROGRAMS</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 4B, OTHER PROGRAM SERVICES:</ReturnReference>
        <Explanation>JUST AS VITAL AS FUNDAMENTAL LABORATORY WORK IN ADVANCING BIOMEDICINE, TRAINING AND EDUCATION PROGRAMS MUST BE ROBUST AND ACCESSIBLE TO EQUIP AND INSPIRE THE NEXT GENERATION OF YOUNG SCIENTISTS. THROUGH ITS SUPPORT OF LECTURES, COURSEWORK, INTERNSHIPS, FELLOWSHIPS, RESIDENCIES AND SCHOLARSHIPS, THE FNIH HELPS TO ENSURE THAT THE PROGRESS OF BIOMEDICAL RESEARCH CONTINUES APACE. THE FNIH FUNDING OFTEN CAN EXPAND SUBSTANTIALLY THE REACH OF TRAINING PROGRAMS BY AFFORDING VIDEOCONFERENCE AND REMOTE-SITE LINKAGES. EXAMPLES INCLUDE: THE BERNARD OSHER FOUNDATION/ NCCAM COMPLEMENTARY AND ALTERNATIVE MEDICINE PRACTITIONER RESEARCH CAREER DEVELOPMENT AWARD IN PARTNERSHIP WITH THE NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE (NCCAM) AT THE NIH, THE OSHER FOUNDATION PROVIDES SUPPORT FOR NCCAM FELLOWSHIPS TO INDIVIDUALS STUDYING COMPLEMENTARY AND ALTERNATIVE MEDICINE. AWARDEES RECEIVE UP TO FIVE YEARS OF INTENSIVE, SUPERVISED CAREER DEVELOPMENT RESEARCH TRAINING IN BIOMEDICAL, BEHAVIORAL OR CLINICAL SCIENCES RELATED TO COMPLEMENTARY AND ALTERNATIVE MEDICINE. SAYER VISION RESEARCH LECTURE NAPOLEONE FERRARA, M.D., PH.D., A FELLOW AT GENENTECH, INC., DELIVERED THE FIFTH SAYER VISION RESEARCH LECTURE AT THE NIH IN JUNE 2011. FERRARA'S ADDRESS WAS ENTITLED, "BASIC SCIENCE AND CLINICAL APPLICATION OF VEGF." EARLY IN HIS CAREER, FERRARA PLAYED A KEY ROLE IN ISOLATING AND CLONING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), A PROTEIN THAT STIMULATES FORMATION OF NEW BLOOD VESSELS. HE IDENTIFIED THE PROTEIN'S ROLE IN ABNORMAL VESSEL GROWTH IN EYE DISEASES SUCH AS WET AGE-RELATED MACULAR DEGENERATION (AMD), A LEADING CAUSE OF VISION LOSS IN OLDER AMERICANS. BUILDING ON THAT RESEARCH, HIS LABORATORY DEVELOPED AN ANTI-VEGF ANTIBODY FRAGMENT, WHICH CAN SIGNIFICANTLY IMPROVE SIGHT IN WET AMD PATIENTS AND LIMIT FURTHER VISION LOSS. THIS WORK EARNED HIM THE 2010 LASKER-DEBAKEY CLINICAL MEDICAL RESEARCH AWARD - ONE OF THE MOST PRESTIGIOUS AWARDS IN SCIENCE. LABORATORY ANIMAL MEDICINE RESIDENT TRAINING PROGRAM THE NIH, THROUGH THE DIVISION OF VETERINARY RESOURCES AND THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE, HAS DEVELOPED THE LABORATORY ANIMAL MEDICINE RESIDENT TRAINING PROGRAM. THIS PROGRAM PREPARES LABORATORY ANIMAL VETERINARIANS AND DEVELOPS A RESOURCE OF SPECIALLY TRAINED LABORATORY ANIMAL VETERINARIANS FOR THE NIH INTRAMURAL RESEARCH PROGRAM AS WELL AS THE ENTIRE LABORATORY ANIMAL AND RESEARCH COMMUNITY.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>PROGRAM THREE: CAPITAL PROJECTS</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 4C, OTHER PROGRAM SERVICES:</ReturnReference>
        <Explanation>THE FOUNDATION'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. THE EDMOND J. SAFRA FAMILY LODGE, FOR EXAMPLE, OPENED IN 2005 TO SERVE AS A COMFORTABLE HOME-AWAY-FROM-HOME FOR FAMILIES THAT COME TO NIH'S CAMPUS IN BETHESDA, MARYLAND TO ACCOMPANY PATIENTS WHO ARE PARTICIPATING IN CLINICAL TRIALS OR RECEIVING TREATMENT AT NIH'S CLINICAL CENTER. SO FAR, THE LODGE HAS HOSTED MORE THAN 40,000 FAMILY MEMBERS AND CAREGIVERS OF ADULT PATIENTS FROM ALL OVER THE WORLD.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>MEMORIALS, AWARDS AND EVENTS</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 4C, OTHER PROGRAM SERVICES:</ReturnReference>
        <Explanation>THE FNIH OVERSEES A NUMBER OF DONOR ADVISED FUNDS CREATED TO SUPPORT SPECIFIC AREAS OF RESEARCH OR FELLOWSHIPS, LECTURES OR AWARDS AT THE NATIONAL INSTITUTES OF HEALTH. THESE FUNDS INCLUDE: THE GRAMLICH MELANOMA RESEARCH FUND SUPPORTS MELANOMA RESEARCH AT THE NIH THROUGH AN ANNUAL GIFT PROVIDED BY THE JACK GRAMLICH FOUNDATION. THE SAYER VISION RESEARCH FUND SUPPORTS AN ANNUAL LECTURE DELIVERED BY AN INVESTIGATOR IN THE AREA OF VISION RESEARCH, AS WELL AS THE SAYER VISION RESEARCH AWARD, A GRANT-IN-AID TO SUPPORT THE RESEARCH OF A PROMISING INDEPENDENT INVESTIGATOR, IN THE EARLY STAGE OF HIS OR HER RESEARCH CAREER IN THE DIVISION OF INTRAMURAL RESEARCH AT THE NATIONAL EYE INSTITUTE. THE ADAM J. BERRY MEMORIAL FUND WAS ESTABLISHED BY MICHAEL AND SUE BERRY IN MEMORY OF THEIR BELOVED SON, ADAM. ADAM CAME FROM AUSTRALIA TO WORK AS A RESEARCH SCIENTIST AT THE NATIONAL CANCER INSTITUTE. THE FUND COMMEMORATES HIS LIFE AND HIS ENTHUSIASM FOR WORK BY MAKING IT POSSIBLE FOR PROMISING YOUNG AUSTRALIAN SCIENTISTS TO TRAVEL TO THE UNITED STATES AND WORK AT THE NIH. THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND SUPPORT A FELLOWSHIP IN THE LABORATORY OF TUMOR IMMUNOLOGY HEADED BY RICHARD CHILDS, M.D., OF THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE. EVENTS BEYOND THE CONFERENCES AND SYMPOSIA THAT ARE ESSENTIAL TO SCIENTIFIC INFORMATION TRANSFER, EVENTS HAVE COME TO PLAY A VITAL ROLE IN BIOMEDICAL RESEARCH-ATTRACTING NONTRADITIONAL PARTNERS AND FUNDERS TO RESEARCH INITIATIVES AND ENGAGING THE PUBLIC IN DISEASE AND HEALTH AWARENESS. FNIH SUPPORTS A VARIETY OF EVENTS, FROM CAREER FAIRS TO EXHIBITS, RECEPTIONS AND MEDIA OPPORTUNITIES, AS EXEMPLIFIED BY THE FOLLOWING: MHEALTH SUMMIT 2011 INAUGURATED IN 2009, THE SUMMIT WAS CONCEIVED AS A VEHICLE TO CONVERGE TWO COMPLEX AND FAST-CHANGING INDUSTRIES - MEDICAL SCIENCE AND TELECOMMUNICATIONS - TO IMPROVE AND EVEN REVOLUTIONIZE HEALTH CARE DELIVERY WORLDWIDE. THE 2011 SUMMIT INCLUDED KEYNOTE AND OTHER SPECIAL SESSIONS, 14 EDUCATION TRACKS IN THE AREAS OF BUSINESS, POLICY, RESEARCH, TECHNOLOGY, MFINANCE AND END-USER SOLUTIONS. THE HEART TRUTH RED DRESS COLLECTION FASHION SHOW 2011 THE RED DRESS COLLECTION FASHION SHOW AT THE MERCEDES BENZ FASHION WEEK IS A SIGNATURE PART OF THE HEART TRUTH CAMPAIGN, AN INITIATIVE OF THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE OF THE NIH WHICH RAISES AWARENESS OF HEART DISEASE AS THE NUMBER-ONE KILLER OF WOMEN IN AMERICA. SINCE 2008, THE FOUNDATION HAS RAISED FUNDS TO SUPPORT THIS EVENT, AND TO FUND A COMMUNITY ACTION PROGRAM THAT AWARDS GRANTS TO ORGANIZATIONS ACROSS THE COUNTRY PROMOTING WOMEN HEART HEALTH. INTERNATIONAL HUMAN MICROBIOME CONGRESS ATTENTION IS INCREASINGLY BEING FOCUSED ON THE HUMAN MICROBIOME - THE MICROBIAL SPECIES THAT RESIDE ON AND WITHIN THE HUMAN BODY - AS A MEANS TO UNDERSTANDING HEALTH AND DISEASE. THIS MEETING, ORGANIZED BY THE FNIH, ATTRACTED MORE THAN 400 PARTICIPANTS WORLDWIDE. RESEARCHERS FROM THE MEDICAL, MICROBIAL AND COMPUTATIONAL FIELDS CONVENED TO DISCUSS THE COMPLEX RELATIONSHIPS BETWEEN THE MICROBIOME AND THE HUMAN BODY, AND WERE JOINED BY FOOD AND PHARMACEUTICAL INDUSTRY REPRESENTATIVES, SCIENCE REPORTERS AND FUNDERS.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION A, LINE 4</ReturnReference>
        <Explanation>- CHANGED THE TITLE OF TOP STAFF FROM "EXECTUIVE DIRECTOR" TO "PRESIDENT AND EXECUTIVE DIRECTOR" - INCREASED THE NUMBER OF DIRECTORS FROM 25 TO 27</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION B, LINE 11</ReturnReference>
        <Explanation>PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS COMPLETED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION B, LINE 12C</ReturnReference>
        <Explanation>THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION B, LINE 15</ReturnReference>
        <Explanation>IN 2008, A CONSULTANT WAS HIRED TO REVIEW, ANALYZE AND DEVELOP A PROCESS OF DETERMINING SALARIES FOR ALL EMPLOYEES OF THE ORGANIZATION. ALL EMPLOYEES WERE INTERVIEWED AND POSITION DESCRIPTIONS DEVELOPED OR AMENDED AS NEEDED. USING MARKET DATA, THE CONSULTANT DEVELOPED PAY BANDS FOR ALL POSITIONS. FINAL RECOMMENDATIONS WERE REVIEWED BY THE EXECUTIVE DIRECTOR. THE EXECUTIVE DIRECTOR'S COMPENSATION IS REVIEWED AND DETERMINED BY THE EXECUTIVE COMMITTEE OF THE BOARD USING LOCAL MARKET DATA.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION C, LINE 19</ReturnReference>
        <Explanation>ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>CHANGES IN NET ASSETS OR FUND BALANCES:</Identifier>
        <ReturnReference>FORM 990, PART XI, LINE 5:</ReturnReference>
        <Explanation>NET UNREALIZED LOSSES ON INVESTMENTS: -51,545.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART XII, LINE 2C:</ReturnReference>
        <Explanation>PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.</Explanation>
      </GeneralExplanation>
    </IRS990ScheduleO>
  </ReturnData>
</Return>